# Sudeep Pharma Limited (SUDEEPPHRM)

> SUDEEPPHRM closed at ₹1,068.30 on 30 Oct 2026, trailing P/E 63.9, market cap ₹12,059 cr, latest results for the quarter ended 30 Sept 2026. Revenue, profit, ROE, debt, own P/E range and sector-peer comparison from the SEBI filing.

Sudeep Pharma Limited (NSE: SUDEEPPHRM) closed at ₹1,068.30 on 30 Oct 2026, against a 52-week range of ₹524.05 – ₹1,378.00.

In the quarter ended 30 Sept 2026 (consolidated, filed 28 Oct 2026) it reported revenue of ₹197 cr and net profit of ₹52 cr, a 26.3% net margin; revenue grew 20.9% and profit grew 19.3% year on year.

On four consecutive filed quarters its trailing P/E is 63.9.

From the balance sheet dated 30 Sept 2026: return on equity 21.7%, ROCE 27.4%, debt-to-equity 0.20, Piotroski F-score 5 of 9.

Against 42 Chemicals peers on NSE: Net margin higher than 95% of 42 sector peers; PBT margin higher than 95% of 42 sector peers; ROE higher than 82% of 40 sector peers.

## Key figures

| Figure | Value |
|---|---|
| Last close | ₹1,068.30 (30 Oct 2026) |
| Change 1 month / 6 months / 1 year | -6.6% / +56.7% / — |
| 52-week low – high | ₹524.05 – ₹1,378.00 |
| Market capitalisation | ₹12,059 cr |
| Trailing P/E | 63.9 |
| Price / book | 12.60 |
| EV / EBITDA | 44.3 |
| Earnings yield | 1.6% |
| TTM EPS | ₹16.71 |
| TTM net profit | ₹189 cr |
| Quarter revenue | ₹197 cr |
| Quarter net profit | ₹52 cr |
| Net margin | 26.3% |
| Revenue growth (YoY) | +20.9% |
| Profit growth (YoY) | +19.3% |
| Return on equity | 21.7% |
| ROCE | 27.4% |
| Debt / equity | 0.20 |
| Current ratio | 2.91 |
| Free cash flow | ₹43 cr |
| Piotroski F-score | 5 / 9 |
| Average daily turnover (50 days) | ₹23.6 cr |

## Questions

### What is the P/E ratio of Sudeep Pharma Limited?

Sudeep Pharma Limited's trailing P/E is 63.9, using the close of 30 Oct 2026 and earnings over the four filed quarters to 30 Sept 2026.

### What were Sudeep Pharma Limited's latest quarterly results?

For the quarter ended 30 Sept 2026, Sudeep Pharma Limited reported revenue of ₹197 cr and net profit of ₹52 cr (consolidated), filed with the exchange on 28 Oct 2026.

### What is Sudeep Pharma Limited's ROE?

Return on equity is 21.7% based on the balance sheet dated 30 Sept 2026.

### Does Sudeep Pharma Limited have debt?

Debt-to-equity is 0.20 on the balance sheet dated 30 Sept 2026.

### What is SUDEEPPHRM's 52-week high and low?

Over the last 52 weeks to 30 Oct 2026, SUDEEPPHRM traded between ₹524.05 and ₹1,378.00.

Sector: [Chemicals](https://trinetra.trade/sectors/chemicals) · Page: https://trinetra.trade/fundamentals/SUDEEPPHRM

_TRINETRA is a research and education tool. Nothing on this site is investment advice or a recommendation to buy or sell any security. Markets carry risk; do your own research and consult a SEBI-registered adviser before investing._